{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:51:42Z","timestamp":1788454302264,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-12942-y","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T06:01:56Z","timestamp":1727676116000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical outcomes and synergistic effect between radiotherapy and immunotherapy in patients with extensive-stage small cell lung cancer: a real-world study"],"prefix":"10.1186","volume":"24","author":[{"given":"Meiling","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaijun","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"issue":"1","key":"12942_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","volume":"7","author":"CM Rudin","year":"2021","unstructured":"Rudin CM, Brambilla E, Faivre-Finn C, et al. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7(1):3.","journal-title":"Nat Rev Dis Primers"},{"key":"12942_CR2","doi-asserted-by":"publisher","first-page":"430","DOI":"10.4143\/crt.2023.931","volume":"56","author":"D Kim","year":"2024","unstructured":"Kim D, Kim HJ, Wu HG, et al. Intrathoracic Progression Is Still the Most Dominant Failure Pattern after First-Line Chemo-immunotherapy in Extensive-Stage Small-Cell Lung Cancer: Implications for Thoracic Radiotherapy. Cancer Res Treat. 2024;56:430\u201341.","journal-title":"Cancer Res Treat"},{"key":"12942_CR3","doi-asserted-by":"publisher","first-page":"4787","DOI":"10.1200\/JCO.2009.23.1548","volume":"28","author":"MA Socinski","year":"2009","unstructured":"Socinski MA, Smit EF, Lorigan P, et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol. 2009;28:4787\u201392.","journal-title":"J Clin Oncol"},{"key":"12942_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","volume":"22","author":"JW Goldman","year":"2021","unstructured":"Goldman JW, Dvorkin M, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22:51\u201365.","journal-title":"Lancet Oncol"},{"key":"12942_CR5","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/JCO.20.01055","volume":"39","author":"SV Liu","year":"2021","unstructured":"Liu SV, Reck M, Mansfield AS, et al. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021;39:619\u201330.","journal-title":"J Clin Oncol"},{"key":"12942_CR6","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"23","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018;23:2220\u20139.","journal-title":"N Engl J Med"},{"key":"12942_CR7","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1200\/JCO.20.00793","volume":"21","author":"CM Rudin","year":"2020","unstructured":"Rudin CM, Awad MM, Navarro A, et al. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. J Clin Oncol. 2020;21:2369\u201379.","journal-title":"J Clin Oncol"},{"key":"12942_CR8","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jama.2022.16464","volume":"12","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Han L, Wu L, et al. Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial. JAMA. 2022;12:1223\u201332.","journal-title":"JAMA"},{"key":"12942_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S0140-6736(14)61085-0","volume":"385","author":"BJ Slotman","year":"2015","unstructured":"Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015;385:36\u201342.","journal-title":"Lancet"},{"key":"12942_CR10","doi-asserted-by":"publisher","first-page":"1132482","DOI":"10.3389\/fimmu.2023.1132482","volume":"14","author":"H Li","year":"2023","unstructured":"Li H, Zhao Y, Ma T, et al. Radiotherapy for extensive-stage small-cell lung cancer in the immunotherapy era. Front Immunol. 2023;14:1132482.","journal-title":"Front Immunol"},{"key":"12942_CR11","doi-asserted-by":"publisher","first-page":"215719","DOI":"10.1016\/j.canlet.2022.215719","volume":"541","author":"Y Tian","year":"2022","unstructured":"Tian Y, Ma J, Jing X, et al. Radiation therapy for extensive-stage small-cell lung cancer in the era of immunotherapy. Cancer Lett. 2022;541:215719.","journal-title":"Cancer Lett"},{"key":"12942_CR12","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","volume":"17","author":"SJ Antonia","year":"2016","unstructured":"Antonia SJ, L\u00f3pez-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial. Lancet Oncol. 2016;17:883\u201395.","journal-title":"Lancet Oncol"},{"key":"12942_CR13","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1200\/JCO.2017.72.5069","volume":"34","author":"PA Ott","year":"2017","unstructured":"Ott PA, Elez E, Hiret S, et al. Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. J Clin Oncol. 2017;34:3823\u20139.","journal-title":"J Clin Oncol"},{"key":"12942_CR14","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1470-2045(22)00224-8","volume":"23","author":"J Wang","year":"2022","unstructured":"Wang J, Zhou C, Yao W, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:739\u201347.","journal-title":"Lancet Oncol"},{"key":"12942_CR15","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1111\/1759-7714.14874","volume":"15","author":"J Xie","year":"2023","unstructured":"Xie J, Chen M, Han H, et al. Clinical impact of first-line PD-1 or PD-L1 inhibitors combined with chemotherapy in extensive-stage small cell lung cancer patients: A real-world multicenter propensity score-matched study. Thorac Cancer. 2023;15:1327\u201338.","journal-title":"Thorac Cancer"},{"key":"12942_CR16","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1001\/jamaoncol.2019.5367","volume":"6","author":"J Duan","year":"2020","unstructured":"Duan J, Cui L, Zhao X, et al. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2020;6:375\u201384.","journal-title":"JAMA Oncol"},{"key":"12942_CR17","doi-asserted-by":"crossref","unstructured":"Cheng Y, Fan Y, Zhao Y, et al. Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial. J Thorac Oncol. 2024;7:S1556\u20130864(24)00115\u20131.","DOI":"10.1016\/j.jtho.2024.03.008"},{"key":"12942_CR18","doi-asserted-by":"crossref","unstructured":"Cheng Y, Liu Y, Zhang W, et al. EXTENTORCH: A randomized, phase III trial of toripalimab versus placebo, in combination with chemotherapy as a first-line therapy for patients with extensive stage small cell lung cancer (ES-SCLC). 2023; ESMO. LBA93.","DOI":"10.1016\/j.annonc.2023.10.096"},{"key":"12942_CR19","doi-asserted-by":"crossref","unstructured":"Ying Cheng, Jie Wang, Wenxiu Yao, et al. Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC). 2023; ESMO Asia. 519P.","DOI":"10.1016\/j.annonc.2023.10.598"},{"key":"12942_CR20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ejca.2019.01.003","volume":"110","author":"S Rathod","year":"2019","unstructured":"Rathod S, Jeremic B, Dubey A, et al. Role of thoracic consolidation radiation in extensive stage small cell lung cancer: A systematic review and meta-analysis of randomised controlled trials. Eur J Cancer. 2019;110:110\u20139.","journal-title":"Eur J Cancer"},{"key":"12942_CR21","doi-asserted-by":"publisher","first-page":"299","DOI":"10.21037\/atm-20-5765","volume":"9","author":"AM Li","year":"2021","unstructured":"Li AM, Zhou H, Xu YY, et al. Role of thoracic radiotherapy in extensive stage small cell lung cancer: a systemic review and meta-analysis. Ann Transl Med. 2021;9:299.","journal-title":"Ann Transl Med"},{"key":"12942_CR22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13014-023-02308-2","volume":"18","author":"J Peng","year":"2023","unstructured":"Peng J, Zhang L, Wang L, et al. Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer. Radiat Oncol. 2023;18:111.","journal-title":"Radiat Oncol"},{"key":"12942_CR23","doi-asserted-by":"publisher","first-page":"3828","DOI":"10.3390\/jcm12113828","volume":"12","author":"Z Xie","year":"2023","unstructured":"Xie Z, Liu J, Wu M, et al. Real-World Efficacy and Safety of Thoracic Radiotherapy after First-Line Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer. J Clin Med. 2023;12:3828.","journal-title":"J Clin Med"},{"key":"12942_CR24","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/cncr.31043","volume":"124","author":"RN Pillai","year":"2018","unstructured":"Pillai RN, Behera M, Owonikoko TK, et al. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature. Cancer. 2018;124:271\u20137.","journal-title":"Cancer"},{"key":"12942_CR25","doi-asserted-by":"publisher","first-page":"S97","DOI":"10.1016\/j.annonc.2022.02.175","volume":"33","author":"SNAA Daher","year":"2022","unstructured":"Daher SNAA, Rottenberg Y, et al. Real-world data of consolidative radiotherapy for extensive stage (ES)-SCLC treated by chemo-immunotherapy (chemo-IO). Ann Oncol. 2022;33:S97\u2013104.","journal-title":"Ann Oncol"},{"key":"12942_CR26","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","volume":"7","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Liu X, Chen D, et al. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct Target Ther. 2022;7:258.","journal-title":"Signal Transduct Target Ther"},{"key":"12942_CR27","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","volume":"24","author":"SC Formenti","year":"2018","unstructured":"Formenti SC, Rudqvist NP, Golden E, et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med. 2018;24:1845\u201351.","journal-title":"Nat Med"},{"key":"12942_CR28","doi-asserted-by":"publisher","first-page":"1289434","DOI":"10.3389\/fimmu.2023.1289434","volume":"14","author":"V Longo","year":"2024","unstructured":"Longo V, Della Corte CM, Russo A, et al. Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy. Front Immunol. 2024;14:1289434.","journal-title":"Front Immunol"},{"key":"12942_CR29","doi-asserted-by":"crossref","unstructured":"Yan Zhang. Phase II study of low-dose radiation (LDRT) plus durvalumab (D) and etoposide\/platinum (EP) as first-line treatment in ES-SCLC (LEAD): Efficacy and safety results. 2024; ELCC 2024.","DOI":"10.1016\/j.esmoop.2024.102767"},{"key":"12942_CR30","doi-asserted-by":"publisher","first-page":"100883","DOI":"10.1016\/j.adro.2021.100883","volume":"7","author":"BH Diamond","year":"2021","unstructured":"Diamond BH, Verma N, Shukla UC, et al. Consolidative Thoracic Radiation Therapy After First-Line Chemotherapy and Immunotherapy in Extensive-Stage Small Cell Lung Cancer: A Multi-Institutional Case Series. Adv Radiat Oncol. 2021;7:100883.","journal-title":"Adv Radiat Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12942-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12942-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12942-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T06:04:40Z","timestamp":1727676280000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12942-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12942"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12942-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4594148\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]},"assertion":[{"value":"17 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Medical Ethics Committee in Weihai Municipal Hospital of Shandong University. Because this study was retrospective, informed consent from the included patients was not required after the approved by the Medical Ethics Committee in Weihai Municipal Hospital of Shandong University, and patient information was anonymized. This study was conducted in accordance with the World Medical Association Declaration of Helsinki, Good Clinical Practices, and local ethical\/legal requirements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1206"}}